Raymond Y Huang, Ph.D., M.D.
This page shows the publications co-authored by Raymond Huang and Lakshmi Nayak.
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
Body CT and PET/CT Detection of Extracranial Lymphoma in Patients with Newly Diagnosed Central Nervous System Lymphoma. Neuro Oncol. 2021 10 06.
Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol. 2021 May 20.
Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 10 02; 91(14):e1355-e1359.
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542.
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.